TY  - JOUR
AU  - Cammarota, Giovanni
AU  - Ianiro, Gianluca
AU  - Tilg, Herbert
AU  - Rajilić-Stojanović, Mirjana
AU  - Kump, Patrizia
AU  - Satokari, Reetta
AU  - Sokol, Harry
AU  - Arkkila, Perttu
AU  - Pintus, Cristina
AU  - Hart, Ailsa
AU  - Segal, Jonathan
AU  - Aloi, Marina
AU  - Masucci, Luca
AU  - Molinaro, Antonio
AU  - Scaldaferri, Franco
AU  - Gasbarrini, Giovanni
AU  - Lopez-Sanroman, Antonio
AU  - Link, Alexander
AU  - De Groot, Pieter
AU  - de Vos, Willem M.
AU  - Hoegenauer, Christoph
AU  - Malfertheiner, Peter
AU  - Mattila, Eero
AU  - Milosavljević, Tomica
AU  - Nieuwdorp, Max
AU  - Sanguinetti, Maurizio
AU  - Simren, Magnus
AU  - Gasbarrini, Antonio
PY  - 2017
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/3706
AB  - Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.
PB  - Bmj Publishing Group, London
T2  - GUT
T1  - European consensus conference on faecal microbiota transplantation in clinical practice
EP  - 580
IS  - 4
SP  - 569
VL  - 66
DO  - 10.1136/gutjnl-2016-313017
ER  - 

@article{
author = "Cammarota, Giovanni and Ianiro, Gianluca and Tilg, Herbert and Rajilić-Stojanović, Mirjana and Kump, Patrizia and Satokari, Reetta and Sokol, Harry and Arkkila, Perttu and Pintus, Cristina and Hart, Ailsa and Segal, Jonathan and Aloi, Marina and Masucci, Luca and Molinaro, Antonio and Scaldaferri, Franco and Gasbarrini, Giovanni and Lopez-Sanroman, Antonio and Link, Alexander and De Groot, Pieter and de Vos, Willem M. and Hoegenauer, Christoph and Malfertheiner, Peter and Mattila, Eero and Milosavljević, Tomica and Nieuwdorp, Max and Sanguinetti, Maurizio and Simren, Magnus and Gasbarrini, Antonio",
year = "2017",
abstract = "Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.",
publisher = "Bmj Publishing Group, London",
journal = "GUT",
title = "European consensus conference on faecal microbiota transplantation in clinical practice",
pages = "580-569",
number = "4",
volume = "66",
doi = "10.1136/gutjnl-2016-313017"
}

Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., Segal, J., Aloi, M., Masucci, L., Molinaro, A., Scaldaferri, F., Gasbarrini, G., Lopez-Sanroman, A., Link, A., De Groot, P., de Vos, W. M., Hoegenauer, C., Malfertheiner, P., Mattila, E., Milosavljević, T., Nieuwdorp, M., Sanguinetti, M., Simren, M.,& Gasbarrini, A.. (2017). European consensus conference on faecal microbiota transplantation in clinical practice. in GUT
Bmj Publishing Group, London., 66(4), 569-580.
https://doi.org/10.1136/gutjnl-2016-313017

Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, De Groot P, de Vos WM, Hoegenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A. European consensus conference on faecal microbiota transplantation in clinical practice. in GUT. 2017;66(4):569-580.
doi:10.1136/gutjnl-2016-313017 .

Cammarota, Giovanni, Ianiro, Gianluca, Tilg, Herbert, Rajilić-Stojanović, Mirjana, Kump, Patrizia, Satokari, Reetta, Sokol, Harry, Arkkila, Perttu, Pintus, Cristina, Hart, Ailsa, Segal, Jonathan, Aloi, Marina, Masucci, Luca, Molinaro, Antonio, Scaldaferri, Franco, Gasbarrini, Giovanni, Lopez-Sanroman, Antonio, Link, Alexander, De Groot, Pieter, de Vos, Willem M., Hoegenauer, Christoph, Malfertheiner, Peter, Mattila, Eero, Milosavljević, Tomica, Nieuwdorp, Max, Sanguinetti, Maurizio, Simren, Magnus, Gasbarrini, Antonio, "European consensus conference on faecal microbiota transplantation in clinical practice" in GUT, 66, no. 4 (2017):569-580,
https://doi.org/10.1136/gutjnl-2016-313017 . .

TY  - JOUR
AU  - Enck, Paul
AU  - Aziz, Qasim
AU  - Barbara, Giovanni
AU  - Farmer, Adam D.
AU  - Fukudo, Shin
AU  - Mayer, Emeran A.
AU  - Niesler, Beate
AU  - Quigley, Eamonn M. M.
AU  - Rajilić-Stojanović, Mirjana
AU  - Schemann, Michael
AU  - Schwille-Kiuntke, Juliane
AU  - Simren, Magnus
AU  - Zipfel, Stephan
AU  - Spiller, Robin C.
PY  - 2016
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/3234
AB  - Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with a high population prevalence. The disorder can be debilitating in some patients, whereas others may have mild or moderate symptoms. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections. Clinical symptoms of IBS include abdominal pain or discomfort, stool irregularities and bloating, as well as other somatic, visceral and psychiatric comorbidities. Currently, the diagnosis of IBS is based on symptoms and the exclusion of other organic diseases, and therapy includes drug treatment of the predominant symptoms, nutrition and psychotherapy. Although the underlying pathogenesis is far from understood, aetiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain-gut interactions. IBS considerably affects quality of life and imposes a profound burden on patients, physicians and the health-care system. The past decade has seen remarkable progress in our understanding of functional bowel disorders such as IBS that will be summarized in this Primer.
PB  - Nature Research, Berlin
T2  - Nature Reviews Disease Primers
T1  - Irritable bowel syndrome
VL  - 2
DO  - 10.1038/nrdp.2016.14
ER  - 

@article{
author = "Enck, Paul and Aziz, Qasim and Barbara, Giovanni and Farmer, Adam D. and Fukudo, Shin and Mayer, Emeran A. and Niesler, Beate and Quigley, Eamonn M. M. and Rajilić-Stojanović, Mirjana and Schemann, Michael and Schwille-Kiuntke, Juliane and Simren, Magnus and Zipfel, Stephan and Spiller, Robin C.",
year = "2016",
abstract = "Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with a high population prevalence. The disorder can be debilitating in some patients, whereas others may have mild or moderate symptoms. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections. Clinical symptoms of IBS include abdominal pain or discomfort, stool irregularities and bloating, as well as other somatic, visceral and psychiatric comorbidities. Currently, the diagnosis of IBS is based on symptoms and the exclusion of other organic diseases, and therapy includes drug treatment of the predominant symptoms, nutrition and psychotherapy. Although the underlying pathogenesis is far from understood, aetiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain-gut interactions. IBS considerably affects quality of life and imposes a profound burden on patients, physicians and the health-care system. The past decade has seen remarkable progress in our understanding of functional bowel disorders such as IBS that will be summarized in this Primer.",
publisher = "Nature Research, Berlin",
journal = "Nature Reviews Disease Primers",
title = "Irritable bowel syndrome",
volume = "2",
doi = "10.1038/nrdp.2016.14"
}

Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., Schwille-Kiuntke, J., Simren, M., Zipfel, S.,& Spiller, R. C.. (2016). Irritable bowel syndrome. in Nature Reviews Disease Primers
Nature Research, Berlin., 2.
https://doi.org/10.1038/nrdp.2016.14

Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EMM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. in Nature Reviews Disease Primers. 2016;2.
doi:10.1038/nrdp.2016.14 .

Enck, Paul, Aziz, Qasim, Barbara, Giovanni, Farmer, Adam D., Fukudo, Shin, Mayer, Emeran A., Niesler, Beate, Quigley, Eamonn M. M., Rajilić-Stojanović, Mirjana, Schemann, Michael, Schwille-Kiuntke, Juliane, Simren, Magnus, Zipfel, Stephan, Spiller, Robin C., "Irritable bowel syndrome" in Nature Reviews Disease Primers, 2 (2016),
https://doi.org/10.1038/nrdp.2016.14 . .